Squarepoint
MRNA icon

Squarepoint’s Moderna MRNA Stock Holding History

Squarepoint’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
16,831
-195,878
-92% -$10.1M ﹤0.01% 2779
2026
Q1 		$10.8M Sell
212,709
-762,486
-78% -$35.6M 0.01% 1024
2025
Q4 		$28.8M Sell
975,195
-187,073
-16% -$5.08M 0.03% 590
2025
Q3 		$30M Buy
1,162,268
+1,053,486
+968% +$29.4M 0.03% 569
2025
Q2 		$3M Sell
108,782
-617,460
-85% -$16.3M ﹤0.01% 1799
2025
Q1 		$20.6M Sell
726,242
-166,626
-19% -$5.91M 0.03% 672
2024
Q4 		$37.1M Buy
892,868
+491,235
+122% +$23.5M 0.04% 482
2024
Q3 		$26.8M Buy
401,633
+247,757
+161% +$22.7M 0.04% 471
2024
Q2 		$18.3M Buy
153,876
+144,880
+1,610% +$18.3M 0.03% 628
2024
Q1 		$959K Sell
8,996
-142,320
-94% -$14.3M ﹤0.01% 2633
2023
Q4 		$15M Buy
151,316
+87,399
+137% +$7.35M 0.03% 705
2023
Q3 		$6.6M Sell
63,917
-134,250
-68% -$15M 0.02% 1008
2023
Q2 		$24.1M Buy
198,167
+32,230
+19% +$4.3M 0.07% 310
2023
Q1 		$25.5M Buy
165,937
+163,470
+6,626% +$27M 0.1% 208
2022
Q4 		$443K Sell
2,467
-108,697
-98% -$17.8M ﹤0.01% 2349
2022
Q3 		$13.1M Buy
+111,164
New +$16.9M 0.07% 337
2022
Q1 		– Sell
-15,489
Closed -$2.61M – 3275
2021
Q4 		$3.93M Sell
15,489
-26,703
-63% -$7.81M 0.01% 891
2021
Q3 		$16.2M Buy
42,192
+36,166
+600% +$13.3M 0.05% 353
2021
Q2 		$1.42M Sell
6,026
-62,666
-91% -$11.2M 0.01% 1388
2021
Q1 		$8.99M Buy
68,692
+8,704
+15% +$1.26M 0.05% 403
2020
Q4 		$6.27M Buy
59,988
+49,472
+470% +$5M 0.05% 390
2020
Q3 		$744K Sell
10,516
-22,084
-68% -$1.54M 0.01% 1164
2020
Q2 		$2.09M Buy
+32,600
New +$1.79M 0.03% 617
2020
Q1 		– Sell
-41,660
Closed -$815K – 2279
2019
Q4 		$815K Buy
+41,660
New +$739K ﹤0.01% 1463
2019
Q3 		– Sell
-75,167
Closed -$1.1M – 2559
2019
Q2 		$1.1M Buy
+75,167
New +$1.61M 0.01% 1212

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Squarepoint's MRNA Position: Q2 2026 in Review

Squarepoint reduced its Moderna (MRNA) stake by 92% in Q2 2026, selling an estimated $10.1M and leaving 16,831 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

Squarepoint first reported a position in MRNA in Q2 2019 and has held it in 25 quarters since. The position peaked at $37.1M in Q4 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Squarepoint held 16,831 shares of Moderna worth $1.18M as of Q2 2026.
  • Squarepoint sold 195,878 Moderna shares in Q2 2026, an estimated $10.1M.
  • Moderna made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2779 holding.
  • Squarepoint first reported a position in Moderna in Q2 2019 and has held it in 25 quarters since.
  • Squarepoint's Moderna position peaked at $37.1M in Q4 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.